Sections

Medication

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Class Summary

These agents have both antimicrobial properties and anti-inflammatory properties. They were originally developed to treat tuberculosis.

Clofazimine (Lamprene)

View full drug information

Clofazimine is a lipophilic rhimophenazine dye with antimicrobial and anti-inflammatory properties originally developed to treat tuberculosis. It inhibits mycobacterial growth and binds preferentially to mycobacterial DNA. Clofazimine has antimicrobial properties, but the mechanism of action unknown.

Although its mechanism of action is unclear, it seems to exert its main effect on neutrophils and monocytes in a variety of ways (eg, stimulating phagocytosis and release of lysosomal enzymes).

Dapsone (Avlosulfon)

View full drug information

Dapsone is bactericidal and bacteriostatic against mycobacteria; its mechanism of action is similar to that of sulfonamides, in which competitive antagonists of PABA prevent formation of folic acid, inhibiting bacterial growth.

Questions

Ramirez CO. Los cenicientos: Problema Clinica. Memoria del Primer Congresso Centroamericano de Dermatologica,. 1957. 122-130.
Convit J, Kerdel-Vegas F. Erythema dyschromicum perstans a hitherto undescribed skin disease. J Invest Dermatol. 1961. 36:457-62.
Berger RS, Hayes TJ, Dixon SL. Erythema dyschromicum perstans and lichen planus: are they related?. J Am Acad Dermatol. 1989 Aug. 21(2 Pt 2):438-42. [QxMD MEDLINE Link].
Kark EC, Litt JZ. Ashy dermatosis--a variant of lichen planus?. Cutis. 1980 Jun. 25(6):631-3. [QxMD MEDLINE Link].
Naidorf KF, Cohen SR. Erythema dyschromicum perstans and lichen planus. Arch Dermatol. 1982 Sep. 118(9):683-5. [QxMD MEDLINE Link].
Kumarasinghe SPW, Pandya A, Chandran V, Rodrigues M, Dlova NC, Kang HY, et al. A global consensus statement on ashy dermatosis, erythema dyschromicum perstans, lichen planus pigmentosus, idiopathic eruptive macular pigmentation, and Riehl's melanosis. Int J Dermatol. 2019 Mar. 58 (3):263-272. [QxMD MEDLINE Link].
Udompanich S, Vachiramon V. Acquired Macular Pigmentation of Unknown Etiology. J Clin Aesthet Dermatol. 2019 Jan. 12 (1):38-46. [QxMD MEDLINE Link].
Penagos H, Jimenez V, Fallas V, O'Malley M, Maibach HI. Chlorothalonil, a possible cause of erythema dyschromicum perstans (ashy dermatitis). Contact Dermatitis. 1996 Oct. 35(4):214-8. [QxMD MEDLINE Link].
Molinero J, Vilata JJ, Nagore E, Obon L, Grau C, Aliaga A. Ashy dermatosis in an HIV antibody-positive patient. Acta Derm Venereol. 2000 Jan-Feb. 80(1):78-9. [QxMD MEDLINE Link].
Nelson MR, Lawrence AG, Staughton RC, Gazzard BG. Erythema dyschromicum perstans in an HIV antibody-positive man. Br J Dermatol. 1992 Dec. 127(6):658-9. [QxMD MEDLINE Link].
Correa MC, Memije EV, Vargas-Alarcon G, et al. HLA-DR association with the genetic susceptibility to develop ashy dermatosis in Mexican Mestizo patients. J Am Acad Dermatol. 2007 Apr. 56(4):617-20. [QxMD MEDLINE Link].
Vega-Memije ME, Dominguez-Soto L. Ashy dermatosis. Int J Dermatol. 2010 Feb. 49(2):228-9. [QxMD MEDLINE Link].
Vazquez-Lopez F, Vidal AM, Zalaudek I. Dermoscopic subpatterns of ashy dermatosis related to lichen planus. Arch Dermatol. 2010 Jan. 146(1):110. [QxMD MEDLINE Link].
Carboni I, Costanzo A, Campione E, Paterno EJ, Chimenti S. [Ashy dermatosis: clinico-pathological associations in two cases]. Clin Ter. 2008 Sep-Oct. 159(5):321-3. [QxMD MEDLINE Link].
Silverberg NB, Herz J, Wagner A, Paller AS. Erythema dyschromicum perstans in prepubertal children. Pediatr Dermatol. 2003 Sep-Oct. 20(5):398-403. [QxMD MEDLINE Link].
Keisham C, Sarkar R, Garg VK, Chugh S. Ashy dermatosis in an 8-year-old Indian child. Indian Dermatol Online J. 2013 Jan. 4(1):30-2. [QxMD MEDLINE Link]. [Full Text].
Torrelo A, Zaballos P, Colmenero I, Mediero IG, de Prada I, Zambrano A. Erythema dyschromicum perstans in children: a report of 14 cases. J Eur Acad Dermatol Venereol. 2005 Jul. 19(4):422-6. [QxMD MEDLINE Link].
Tisack AM, Huggins RH, Lim HW. Erythema dyschromicum perstans in a caucasian pediatric patient. J Drugs Dermatol. 2013 Jul 1. 12(7):819-20. [QxMD MEDLINE Link].
Zaynoun S, Rubeiz N, Kibbi AG. Ashy dermatoses--a critical review of the literature and a proposed simplified clinical classification. Int J Dermatol. 2008 Jun. 47(6):542-4. [QxMD MEDLINE Link].
Antonov NK, Braverman I, Subtil A, Halasz CL. Erythema dyschromicum perstans showing resolution in an adult. JAAD Case Rep. 2015 Jul. 1 (4):185-7. [QxMD MEDLINE Link].
Tomii K, Fujimoto A, Yokoyama R, Kabata Y, Fujita S, Hayashi R, et al. Erythema dyschromicum perstans with a Wagyu beef-like appearance on dermoscopy. J Eur Acad Dermatol Venereol. 2020 Mar. 34 (3):e141-e142. [QxMD MEDLINE Link].
Mizukawa Y, Shiohara T. Fixed drug eruption presenting as erythema dyschromicum perstans: a flare without taking any medications. Dermatology. 1998. 197(4):383-5. [QxMD MEDLINE Link].
Kratzsch D, Simon JC, Ziemer M. Lichen planus-like drug eruption on anti-PD-1 therapy. J Dtsch Dermatol Ges. 2017 Dec. 15 (12):1238-1240. [QxMD MEDLINE Link].
Li S, Arvisais-Anhalt S, Vandergriff T, Le LQ. Ashy dermatosis-like hyperpigmentation in a patient taking hydroxyurea. JAAD Case Rep. 2020 Sep. 6 (9):797-800. [QxMD MEDLINE Link].
Ransohoff KJ, Pugliese SB, Zaba LC, Rieger KE, Kwong BY. Epidermal growth factor receptor inhibitor therapy-associated erythema dyschromicum perstans-like eruption: a case series. Br J Dermatol. 2020 Dec. 183 (6):1130-1132. [QxMD MEDLINE Link].
Tienthavorn T, Tresukosol P, Sudtikoonaseth P. Patch testing and histopathology in Thai patients with hyperpigmentation due to Erythema dyschromicum perstans, Lichen planus pigmentosus, and pigmented contact dermatitis. Asian Pac J Allergy Immunol. 2014 Jun. 32(2):185-92. [QxMD MEDLINE Link].
Tétu P, Jachiet M, de Masson A, Hurabielle C, Rybojad M, Michonneau D, et al. Chronic graft versus host disease presenting as lichen planus pigmentosus. Bone Marrow Transplant. 2018 Feb 6. [QxMD MEDLINE Link].
Volz A, Metze D, Bohm M, Bruckner-Tuderman L, Nashan D. Idiopathic eruptive macular pigmentation in a 7-year-old girl: case report and discussion of differences from erythema dyschromicum perstans. Br J Dermatol. 2007 Oct. 157(4):839-40. [QxMD MEDLINE Link].
Srivastava N, Solanki LS, Chand S, Garbyal RS, Singh S. Ashy dermatosis-like pigmentation due to ethambutol. Indian J Dermatol Venereol Leprol. 2008 May-Jun. 74(3):281-2. [QxMD MEDLINE Link].
Molinar VE, Taylor SC, Pandya AG. What's new in objective assessment and treatment of facial hyperpigmentation?. Dermatol Clin. 2014 Apr. 32(2):123-35. [QxMD MEDLINE Link].
Cestari TF, Dantas LP, Boza JC. Acquired hyperpigmentations. An Bras Dermatol. 2014 Jan-Feb. 89(1):11-25. [QxMD MEDLINE Link]. [Full Text].
Jeon J, Kim JH, Ahn JW, Song HJ. Poikiloderma vasculare atrophicans showing features of ashy dermatosis in the beginning. Ann Dermatol. 2015 Apr. 27(2):197-200. [QxMD MEDLINE Link]. [Full Text].
Tamer F. Coexistence of erythema dyschromicum perstans and vitiligo: a case report and review of the literature. Acta Dermatovenerol Alp Pannonica Adriat. 2016 Dec. 25 (4):77-78. [QxMD MEDLINE Link].
Vega ME, Waxtein L, Arenas R, Hojyo T, Dominguez-Soto L. Ashy dermatosis and lichen planus pigmentosus: a clinicopathologic study of 31 cases. Int J Dermatol. 1992 Feb. 31(2):90-4. [QxMD MEDLINE Link].
Oiso N, Tsuruta D, Imanishi H, Kobayashi H, Kawada A. Erythema Dyschromicum Perstans in a Japanese Child. Pediatr Dermatol. 2011 Nov 8. [QxMD MEDLINE Link].
Arbiser JL, Moschella SL. Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol. 1995 Feb. 32(2 Pt 1):241-7. [QxMD MEDLINE Link].
Tlougan BE, Gonzalez ME, Mandal RV, Kundu RV, Skopicki D. Erythema dyschromicum perstans. Dermatol Online J. 2010 Nov 15. 16(11):17. [QxMD MEDLINE Link].
Fabbrocini G, Cacciapuoti S, Izzo R, Mascolo M, Staibano S, Monfrecola G. Efficacy of Narrowband UVB Phototherapy in Erythema Dyschromicum Perstans Treatment: Case Reports. Acta Dermatovenerol Croat. 2015 Apr. 23(1):63-5. [QxMD MEDLINE Link].
Muñoz C, Chang AL. A case of Cinderella: erythema dyschromicum perstans (ashy dermatosis or dermatosis cinecienta). Skinmed. 2011 Jan-Feb. 9(1):63-4. [QxMD MEDLINE Link].
Wang F, Zhao YK, Wang Z, Liu JH, Luo DQ. Erythema Dyschromicum Perstans Response to Isotretinoin. JAMA Dermatol. 2016 Mar 2. [QxMD MEDLINE Link].
Bahadir S, Cobanoglu U, Cimsit G, Yayli S, Alpay K. Erythema dyschromicum perstans: response to dapsone therapy. Int J Dermatol. 2004 Mar. 43(3):220-2. [QxMD MEDLINE Link].
Wolfshohl JA, Geddes ER, Stout AB, Friedman PM. Improvement of erythema dyschromicum perstans using a combination of the 1,550-nm erbium-doped fractionated laser and topical tacrolimus ointment. Lasers Surg Med. 2017 Jan. 49 (1):60-62. [QxMD MEDLINE Link].
Ercan N. Erythema dyschromicum perstans in an infant with positive Darier sign: A case report successfully treated with tacrolimus. Dermatol Ther. 2020 Nov. 33 (6):e14175. [QxMD MEDLINE Link].
Gougerot MH. Lichen atypiques ou invisibles pigmentogenes reveles par des pigmentations. Bull Soc Fr Dermatol Syphiligr. 1935. 42:792-4.
Gougerot MH. Lichen atypiques ou invisibles pigmentogenes. Bull Soc Fr Dermatol Syphiligr. 1935. 42:894-8.
Lambert WC, Schwartz RA, Hamilton GB. Erythema dyschromicum perstans. Cutis. 1986 Jan. 37(1):42-4. [QxMD MEDLINE Link].
Schwartz RA. Erythema dyschromicum perstans: the continuing enigma of Cinderella or ashy dermatosis. Int J Dermatol. 2004 Mar. 43(3):230-2. [QxMD MEDLINE Link].

Media Gallery

Ash-colored, partially confluent, macular lesions over the patient's back. Reprint with permission from Cutis 1986; 37: 42-44.
Close-up photograph shows ash-colored macular lesions and lack of an inflammatory border. Reprint with permission from Cutis 1986; 37: 42-44.
Photomicrograph of a lesion on the patient's back shows slight basilar vacuolar change, extensive pigment incontinence, dilatation of dermal lymphatics, and lack of inflammation (hematoxylin & eosin, original magnification X24.8). Reprint with permission from Cutis 1986; 37: 42-44.
Higher-power photograph shows slight vacuolar basilar change, marked dilatation of intradermal lymphatics, incontinence of melanin pigment, and lack of inflammation (hematoxylin & eosin, original magnification X238). Reprint with permission from Cutis 1986; 37: 42-44.

of 4

Author

Robert A Schwartz, MD, MPH Professor and Head of Dermatology, Professor of Pathology, Professor of Pediatrics, Professor of Medicine, Rutgers New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, New York Academy of Medicine, Royal College of Physicians of Edinburgh, Sigma Xi, The Scientific Research Honor Society

Disclosure: Nothing to disclose.

Coauthor(s)

Santiago A Centurion, MD Dermatologist, Dermatology Associates of Central NJ

Santiago A Centurion, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Society for Dermatologic Surgery, American Society for MOHS Surgery, American Society of Dermatopathology, Sigma Xi, The Scientific Research Honor Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Michael J Wells, MD, FAAD Dermatologic/Mohs Surgeon, The Surgery Center at Plano Dermatology

Michael J Wells, MD, FAAD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Texas Medical Association

Disclosure: Nothing to disclose.

Jeffrey P Callen, MD Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Jeffrey P Callen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, American College of Rheumatology

Disclosure: Received income in an amount equal to or greater than $250 from: Genentech as a consultant for a potential study on a drug that has yet to be approved for any use<br/>Received honoraria from UpToDate for author/editor; Received royalty from Elsevier for book author/editor; Received dividends from trust accounts, but I do not control these accounts, and have directed our managers to divest pharmaceutical stocks as is fiscally prudent from Stock holdings in various trust accounts include some pharmaceutical companies and device makers for these trust accounts; I served on a safety monitoring committee for Principia Biopharma (ended 9-2021) for: Stocks held in various trust accounts: Allergen; Pfizer; 3M; Johnson and Johnson; Merck; Abbott Laboratories; AbbVie; Procter and Gamble; Amgen; Gilead.

Chief Editor

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Shyam Verma, MBBS, DVD, FAAD Clinical Associate Professor, Department of Dermatology, University of Virginia School of Medicine; Adjunct Associate Professor, Department of Dermatology, State University of New York at Stonybrook School of Medicine; Adjunct Associate Professor, Department of Dermatology, University of Pennsylvania School of Medicine

Shyam Verma, MBBS, DVD, FAAD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Erythema Dyschromicum Perstans Medication

Medication Summary

Leprostatics

Class Summary

Clofazimine (Lamprene)

Clofazimine (Lamprene)

Dapsone (Avlosulfon)

Dapsone (Avlosulfon)

Erythema Dyschromicum Perstans Medication

Medication Summary

Leprostatics

Class Summary

Clofazimine (Lamprene)

Clofazimine (Lamprene)

Dapsone (Avlosulfon)

Dapsone (Avlosulfon)

References

Tables

Contributor Information and Disclosures

What would you like to print?